GlobeNewsWire
30 Mar 2026, 11:30 UTC · 26w ago
Verdict
Headline takes no side. We score IFRX −0.40 across three claims — moderately bearish.
−0.40moderately bearish
More negative than 69% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The Phase 3 study of vilobelimab in pyoderma gangrenosum was terminated early due to futility.
So whatTrial termination for futility is a major clinical failure that typically precludes immediate regulatory approval and destroys short-term valuation for that specific indication.
More negative than 99% of claims this week
InflaRx expects any future development activities for vilobelimab in pyoderma gangrenosum to be conducted only in collaboration with a partner.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 85% of claims this week
Vilobelimab demonstrated a positive safety profile and a significant reduction in C5a levels during the Phase 3 study.
More positive than 53% of claims this week
Which stocks this story touches
More negative than 69% of ticker scores this week
The company's Phase 3 study for vilobelimab was terminated early due to futility, despite some encouraging secondary signals.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
41m ago
+88.6%
Price is moving against the score
$1.72 vs $0.9119 close before publication (Mar 27) · not market-adjusted
IFRX chart →
